<html>
<head>PUBMED IDs for MISRII</head>
<body bgcolor='#C5F0F2'><h1>MISRII</h1><a href='https://pubmed.ncbi.nlm.nih.gov/12724325/'>Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.</a> May 2  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/16007601/'>Unusual mixed gonadal dysgenesis associated with Müllerian duct persistence, polygonadia, and a 45,X/46,X,idic(Y)(p) karyotype.</a> July 12  2005<br><a href='https://pubmed.ncbi.nlm.nih.gov/16687449/'>Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.</a> May 12  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/21573503/'>Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.</a> January 14  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/28197641/'>Müllerian inhibiting substance inhibits an ovarian cancer cell line via β-catenin interacting protein deregulation of the Wnt signal pathway.</a> February 16  2017<br></body></html>
